Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab induction study in moderate to severe Crohn's disease
NL-OMON36532Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease and inflammatory bowel disease (IBD) comparing Vedolizumab with Placebo (2 arms). Primary endpoint: Clinical remission at Week 6 in TNF-alpha antagonist failure subpopulation. Started Dec 2010; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON36532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36532.